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Abstract
Background: This randomized, double-blind, multi-center, non-inferiority trial was conducted to assess the efficacy and
safety of a cross-linked hyaluronate (XLHA, single injection form) compared with a linear high molecular hyaluronate
(HMWHA, thrice injection form) in patients with symptomatic knee osteoarthritis.
Methods: Two hundred eighty seven patients with osteoarthritis (Kellgren-Lawrence grade I to III) were randomized to
each group. Three weekly injections were given in both groups but two times of saline injections preceded XLHA
injection to maintain double-blindness. Primary endpoint was the change of weight-bearing pain (WBP) at 12 weeks after
the last injection. Secondary endpoints included Western Ontario and McMaster Universities Osteoarthritis index; patient’s
and investigator’s global assessment; pain at rest, at night, or in motion; OMERACT-OARSI responder rate; proportion of
patients achieving at least 20 mm or 40% decrease in WBP; and rate of rescue medicine use and its total consumption.
Results: Mean changes of WBP at 12 weeks after the last injection were −33.3 mm with XLHA and −29.2 mm with
HMWHA, proving non-inferiority of XLHA to HMWHA as the lower bound of 95% CI (−1.9 mm, 10.1 mm) was well
above the predefined margin (−10 mm). There were no significant between-group differences in all secondary
endpoints. Injection site pain was the most common adverse event and no remarkable safety issue was identified.
Conclusions: This study demonstrated that a single injection of XLHA was non-inferior to three weekly injections of
HMWHA in terms of WBP reduction, and supports XLHA as an effective and safe treatment for knee osteoarthritis.
Trial registration: ClinicalTrials.gov (NCT01510535). This trial was registered on January 6, 2012.
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Background
In the treatment of mild to moderate osteoarthritis (OA),
pharmacologic treatments including analgesics and non-
steroidal anti-inflammatory drugs (NSAIDs) are recom-
mended along with various non-pharmacologic modalities
such as exercise and weight reduction. However, most of
the currently available pharmacologic treatment has its
own limitations regarding tolerability and durability. In
the search of an alternative treatment option, attention
has turned to viscosupplementation, of which the concept
was based on the recognition that synovial hyaluronan
(HA) is decreased in its concentration and length of its
chain in OA patients [1]. HA is a natural viscoelastic sub-
stance known to play an important role in lubricating,
shock-absorbing, and maintaining the normal physiology
of articular cartilage [2].
Since late 1990s, many studies have investigated the effi-
cacy and safety of various intra-articular HA (IAHA)
preparations of various molecular weights (MW), espe-
cially for knee OA. The compiled available evidence [3–5]
suggests positive effect of IAHA preparations in pain re-
duction and functional improvement and a conditional
recommendation was given for IAHA to treat knee OA by
professional guidelines [6, 7]. Still, some controversies
exist on the clinical efficacy of the intra-articular injection
of various HA preparations [8–12]. Therefore, further in-
vestigations to gather qualitative data from randomized,
controlled trials of various comparisons are warranted.
In the light of this context, we had planned a randomized,
double-blind comparative study to investigate the efficacy
and safety of a cross-linked HA (XLHA) compared with
those of a linear high molecular weight HA (HMWHA).
Increase in the MW, stability, and viscosity of HA by
cross-linking has been known to result in an extended dur-
ation of action with less number of intra-articular injections
[13–15]. The present study was therefore designed to assess
the non-inferiority of the single injection of XLHA to three
weekly injections of HMWHA and to compare the efficacy
and safety of the two preparations in patients with mild to
symptomatic moderate knee OA.
Methods
Materials
A newly developed XLHA product with MW ≥
10000 kDa, LBSA0103 (LG life sciences, Iksan, South
Korea), and Hyruan Plus® (LG life sciences, Iksan, South
Korea), a linear HMWHA of mean MW of 3000 kDa
were used for this clinical trial. Both preparations are
derived from bacteria (Streptococcus zooepidermicus).
Hyruan Plus® has been used in more than 25 countries
with the indications of OA of the knee, shoulder, hip,
and ankle although specific indication may be different
in each country; and its efficacy and safety have been
published in several preclinical [16, 17] and clinical trials
[18, 19]. For LBSA0103, HA is modified to form a bigger
and more stable HA by using 1, 4-butanediol diglycidyl
ether (BDDE) as the cross-linker of which the safety and
metabolism have been well established [20].
Study design
This was a randomized, double-blind, multi-center (12 in-
vestigational sites) study to evaluate the efficacy and safety
of XLHA compared with HMWHA, in patients with
symptomatic knee OA. After going through screening at
Visit 1 and washout-period of 2 weeks, eligible patients
were randomized into each group (XLHA or HMWHA)
in a 1:1 ratio to receive three intra-articular injections of
the assigned intervention (Visit 2-Visit 4). Study group re-
ceived two placebo (saline) and one XLHA injections and
control group received three HMWHA injections. The
two injection of placebo in the study group was inevitable
to maintain the double blindness of this study. A block
randomization scheme with a block size of 4, stratified by
investigational site and involvement of unilateral or
bilateral knees, was generated using SAS® version 9.1 (SAS
Institute Inc., Cary, NC, USA). Patients were followed up
at 1 week, 6 weeks, and 12 weeks after the last injection
(Visit 5-Visit 7). Total study period (FPI-LPO) was
11 months (Dec. 2011-Oct. 2012).
Patients, investigators, and all study related personnel
including study monitors were blinded to the assigned
treatment. To maintain double-blind conditions, injections
were given only by a dedicated independent non-blinded
investigator and efficacy assessments were made by another
independent investigator in each site, who was also
concealed from the treatment information.
The study was coducted in accordance with the ethical
principles of Helsinki Declaration, good clinical practice,
and applicable local regulations. The government regula-
tory authority and the IRB of each investigational site
granted approval for the study and informed consent was
obtained from all individual participants included in the
study. The patients who enrolled in this clinical trial did
not receive any inappropriate financial compensation
except transportation fee.
Study population
Patients aged 40 years or older with knee OA that satis-
fies the diagnostic criteria of American College of
Rheumatology [21] and Kellgren-Lawrence [22] grade I
to III by X-ray were enrolled. All patients underwent
simple radiographs including standing anteroposterior
and lateral views, standing posteroanterior view with 45°
knee flexion (Rosenberg view), and merchant view. The
severity of OA based on Kellgren-Lawrence grade was
evaluated by two independent experienced radiologists
who were blinded to the assigned treatment. The
inclusion criteria were Kellgren-Lawrence grade I to III
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by X-ray, weight-bearing pain (WBP) ≥40 mm in the af-
fected knee by 100 mm visual analog scale (VAS), per-
sistent pain at least in one knee despite of treatments
with NSAIDs or other analgesics, and willing to discontinue
current OA treatments. The exclusion criteria were the fol-
lowings: body mass index (BMI) >32; rheumatoid arthritis
or other metabolic/inflammatory arthritis; septic arthritis;
skin lesion in the affected knee; secondary knee OA; dis-
eases accompanying severe pain such as Sudek’s atrophy,
Paget’s disease, or spinal disc herniation; polyarticular OA
that may hinder pain assessment of knee; significant loss of
patellofemoral joint space confirmed by X-ray; patients with
severe knee joint effusion; heart, liver, and kidney disorder;
need of anticoagulant medication except aspirin; pregnant
or lactating women; women with child-bearing potential
not willing to use effective contraception; history of surgical
procedures in the affected knee within 12 months; joint re-
placement surgery of the affected knee; use of previous OA
treatments that would interfere with study assessment such
as IAHA in the affected knee within 9 months, IAHA in
the other joints within 6 months, IA steroid injection
within 3 months, or oral steroids within a month; use of
contraindicated treatment (refer to 4.4) during washout
period; and use of any analgesics including acetaminophen
or aspirin within 24 h from randomization; administration
of anesthetics within 48 h from randomization.
Intervention
One dedicated independent investigator per institute per-
formed the injections. The study group received two times
of weekly injections of placebo (phosphate buffered saline,
18 mg/2 mL/injection) followed by an injection of XLHA
(60 mg/3 mL/injection), on the third week. The control
group received three weekly injections of HMWHA
(20 mg/2 mL/injection). Injections were given using 21G
needles with strict aseptic techniques. Any effusions, if
present, were aspirated into a separate syringe before the
administration of the XLHA or HMWHA, the same nee-
dle was left in place for the XLHA or HMWHA prefilled
syringe injection. During the entire study period, patients
were not allowed to use steroid, NSAIDs, chondroitin sul-
fate/glucosamine or other pain relieving methods includ-
ing physical therapy. Low dose aspirin (≤300 mg/day)
taken for a cardiovascular condition was allowed. Acet-
aminophen (≤4 g/day) taken as a rescue therapy was
allowed. However, these agents should be stopped 24 h
before each assessment visit.
Outcome measures
The primary endpoint was the change of weight-bearing
pain (WBP) assessed by 100 mm visual analogue scale
from baseline (Visit 2) to Visit 7. This variable was also
evaluated for Visit 5 and Visit 6 as secondary endpoints.
Changes in the following secondary endpoints were also
assessed at Visit 5, 6, and 7: Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC)
total score; WOMAC subscale (pain, function, stiffness)
score; patient’s global assessment; investigator’s global
assessment; pain at rest; pain at night; pain in motion;
severity of swelling and tenderness; range of knee joint
motion at baseline and follow-up visits; the proportion
of patients satisfying responder criteria suggested by the
Outcome Measures for Rheumatology Committee and
Osteoarthritis Research Society International Standing
Committee for Clinical Trials Response Criteria Initia-
tive (OMERACT-OARSI) [23]; WBP responder rate,
which was defined as the proportion of patients achiev-
ing at least 20 mm of decrease or 40% reduction from
baseline in WBP; and the proportion of patients using
rescue medicine (acetaminophen); total consumption of
the rescue medicine.
Safety was assessed by adverse events (AEs). All of the
AEs that occured during the study period were collected
at each visit by the investigator’s observation and also by
asking any experience of AEs to the patients. The AEs
were collected regardless of the severity or relationship to
the study drugs. The AEs were classified according to the
Medical Dictionary for Regulatory Activities (MedDRA
Ver. 15.0). Particular attention was paid to injection site
reactions (erythema, swelling, pain, or warmth), which
was collected by solicitation method using patients’ diary
cards for 7 days after each injection. The vital signs and la-
boratory tests were evaluated and clinically significant
change was collected as AEs during the study.
Statistical analysis
The primary purpose was to prove the non-inferiority of
XLHA to HMWHA in terms of decreasing the WBP. As-
suming a standard deviation of 24.3 based on the phase III
study of HMWHA and the non-inferiority margin of
−10 mm [24], the sample size needed for the non-
inferiority test was 93 per group, which would provide 80%
power at a significance level of 5%. The final sample size
was 266 (133 per group) to accommodate 30% drop-out or
protocol violation.
For the primary endpoint, two-sided 95% confidence
interval (CI) for between-group difference (HMWHA -
XLHA) was calculated; and if the lower bound of the CI
was greater than -10 mm, the non-inferiority of XLHA to
HMWHA was to be declared. Missing values of the pri-
mary endpoint were replaced by the last available data ac-
cording to the last observation carried forward approach.
For secondary endpoints, between-group differences and
the differences from baseline were tested. Depending on
the data normality of continuous variables, a two sample
t-test or a Wilcoxon's rank sum test was used for the
between-group comparison whereas a paired t-test or a
Wilcoxon’s signed rank test was used for the within-group
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comparison. For categorical variables, the between-group
comparison was tested using a Chi-square test or a Fish-
er’s exact test. All statistical analyses were performed using
SAS® software version 9.1 (SAS Institute, Cary, NC, USA).
Results
Patient population
During the study period, 310 patients were screened and
23 were excluded due to consent withdrawal (12) or non-
eligibility (11); 287 were randomized; 276 received
planned series of study treatments; 266 completed the
12 weeks of follow-up visits (Fig. 1). Excluding two pa-
tients who withdrew their consent before receiving an in-
jection, 285 patients were included in the safety analysis.
Among these 285 patients, two were never evaluated for
efficacy outcome after baseline and were excluded from
the efficacy analysis. Thus full analysis set (FAS) included
283 patients whereas per-protocol set (PPS) included 208
patients after exlcuding 75 patients with major protocol
violations. No between-group difference in the drop-out
or protocol violation rates was noted (Fig. 1). Patients
demographics and baseline characteristics were compar-
able between the two groups (Table 1).
Efficacy
The changes in WBP from baseline to Visit 5, 6, and 7
in PPS are shown in Fig. 2. Significant reduction in WBP
was observed at 1 week after the last injection and it
was further evident at week 6 and week 12. The changes
observed at 12 weeks after the last injection were still
significant in both groups and the two-sided 95% CI for
between-group difference was from −1.9 mm to
10.1 mm. Analysis with FAS also showed similar results:
−28 mm in HMWHA and. -32 mm in XLHA; 95% CI,
(−1.3 mm, 9.2 mm). As the lower bound of 95% CI was
greater than the preset margin (−10 mm), the non-
inferiority of XLHA to HMWHA was demonstrated.
Fig 1 Patient Distribution. The bars in the far left indicate each visit; however, the distance between each visit is not proportional to the actual
time because of the limited space. Patients randomized to the cross-linked hyaluronate (XLHA) group received two placebo injections before the
third injections, which was given as XLHA
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Changes in secondary endpoints of continuous variables
at the three follow-up visits (Visit 5, 6, and 7) were all sig-
nificant (P < 0.001) and consistently indicated a general
improvement with both interventions (Table 2). The mag-
nitude of changes in these secondary endpoints was evi-
dent at 6 weeks after the last injection and it was
maintained at 12 weeks. No between-group difference was
observed in any of the secondary endpoints at every
follow-up point. The responder rate by OMERACT-
OARSI and by the predefined responder criteria on WBP
were slightly higher with XLHA than with HMWHA,
although the difference was not statistically significant
(Table 3). The severity of swelling or tenderness in the
knee joint and the proportion of patients with swelling or
tenderness showed meaningful improvement in both
groups throughout the follow-up period. No between-
group difference was observed (Table 2). The range of
knee motion was maintained thoughout the follow-up
period and no between-group difference was observed
(Table 2). Similar proportions of patients used the rescue
medicine: 81/111 (73%) in HMWHA group vs. 62/97
(64%) in XLHA group (P = 0.160). The consumption of
rescue medication during the study period was similar,
and there was a tendency that less proportion of patients
in XLHA group used the rescue medicine than those in
HMWHA group during the period of Visit 6 – Visit 7
(37% vs. 50%, P = 0.053).
Safety
Patients in both groups well tolerated the interventions.
General adverse events were spontaneously reported in
90 patients (32%) during the study: 42 patients (29%) in
HMWHA group experienced 63 adverse events whereas
48 patients (35%) in XLHA group experienced 73 ad-
verse events (P = 0.295). All general adverse events are
summarized by system organ class (Table 4) and adverse
events reported in more than 1% of any group at pre-
ferred term level were also presented (Table 5). Total of
8 patients experienced 9 adverse drug reactions (ADRs),
related with the study interventions; 1 patient (1 event)
in HMWHA group, 7 patients (8 events) in XLHA
group (Table 6). Between-group difference in the rate of
patients experiencing ADR was statistically significant;
however, the significance was not relevant after remov-
ing 3 events that occurred after placebo injections in
XLHA group (0.68% vs. 3.6%, P = 0.113, Fisher’s exact
test). All those 5 events assessed to be related with
XLHA injection did not require medical intervention to
Table 1 Patients demographics and baseline characteristics (Full
Analysis Set)
HMWHA XLHA P-value
(N = 146) (N = 137)
Sex
Male 26 (19%) 32 (22%) 0.54A
Female 111 (81%) 114 (78%)
Age, years 62.38 (8.43) 61.97 (8.64) 0.68B
BMI, kg/m2 24.82 (2.65) 25.14 (2.91) 0.52C
Affected knee, patients
Left 23 (15.75) 22 (16.06) 0.67A
Right 26 (17.81) 30 (21.90)
Bilateral 97 (66.44) 85 (62.04)
Duration of knee OA, years
Left 3.08 (0.08,26) 3.83 (0.08, 22.08) 0.98C
Right 3 (0.08, 26) 4 (0.08, 24.08) 0.19C
K-L grade, patients
Grade I 28 (19.18) 19 (13.87) 0.36A
Grade II 65 (44.52) 59 (43.07)
Grade III 53 (36.30) 59 (43.07)
100 mm VAS on WBP 61.01 (13.22) 61.79 (13.76) 0.68C
WOMAC index
Pain subscore 10.56 (3.31) 10.26 (3.05) 0.33C
Function subscore 34.53 (11.64) 33.75 (10.53) 0.56B
Stiffness subscore 3.97 (1.72) 3.87 (1.61) 0.72C
Total score 49.05 (16.01) 47.88 (14.18) 0.52C
BMI Body mass index, OA osteoarthritis, K-L Kellgren-Lawrence, VAS visual
analogue scale, WBP weight bearing pain, WOMAC Western Ontario and
McMaster Universities Osteoarthritis. Continuous variables are presented with
mean (SD) except duration of knee OA, which is presented with median
(min, max)
A, P-value obtained from Chi-square test; B, P-value obtained from two-sample
t-test; C, P-value obtained from Wilcoxon’s rank sum test
Fig 2 Mean Changes from Baseline in Weight-bearing Pain. Significant
reduction in WBP was observed at 1 week after the last injection
(−18 mm in HMWHA, P< 0.001 and −20 mm in XLHA, P< 0.001); and it
was further evident at week 6 week and week 12. The changes observed
at 12 weeks after the last injection were still significant in both groups
(−29 mm in HMWHA, P< 0.001 and −33 mm in XLHA, P< 0.001).
Reductions in WBP at V5, V6 and V7 from baseline were all significant
(P< 0.001, paired t-test) in both groups. V, Visit; W, Week; Vertical arrows
represent injections of investigational products; Error bars indicate 95%
confidence interval of mean change
Ha et al. BMC Musculoskeletal Disorders  (2017) 18:223 Page 5 of 10
treat them; were mild in intensity except one event (joint
swelling of moderate intensity); and were resolved dur-
ing study period except one event (swelling of mild
intensity).
The incidence of local injection site reactions which
occurred within for 7 days after each injection were
similar in the two groups (P = 0.29-0.94, (Table 7)). The
proportions of patients experiencing local reactions after
HMWHA administration did not differ from those after
placebo administration in the XLHA group. In addition,
the rates did not increase with the subsequent injection
of XLHA on the third week. Those local reactions were
mild or moderate in most of the patients (80%-100%) in
both groups and lasted three to four days. No patients
required a medical treatment to treat them and none
were dropped out because of the local reactions. Two
serious adverse events (1 rib fracture, 1 malignant neoplasm
of lung) were reported during the study period and none
were assessed as related with study interventions. No
clinically significant changes were found in vital signs,
hematology, serum chemistry, and urinalysis.
Discussion
In this randomized, double-blind, controlled trial in 285
patients with symptomatic knee OA, a single intra-
articular injection of XLHA was not inferior to three
weekly injection of HMWHA on efficacy with favorable
safety profile. Patients in both groups showed significant
improvement from baseline throughout the 12-week
follow-up period with regard to WBP, pain in various
Table 2 Mean changes in secondary endpoints from baseline to
follow-up visits (Per-protocol Set)
HMWHA XLHA P-value
N = 111 N = 97
WOMAC
Pain subscore Visit 5 −3.2 (3.15) −2.77 (3.28) 0.51B
Visit 6 −3.87 (3.53) −3.39 (3.64) 0.54B
Visit 7 −4.23 (3.7) −3.96 (3.37) 0.59A
Function subscore Visit 5 −8.05 (9.73) −7.89 (10.23) 0.91A
Visit 6 −11.03 (11.84) −10.74 (10.84) 0.86A
Visit 7 −12.09 (12.47) −12.57 (9.58) 0.76A
Stiffness subscore Visit 5 −0.99 (1.67) −0.88 (1.6) 0.58B
Visit 6 −1.21 (1.72) −1.18 (1.59) 0.94B
Visit 7 −1.34 (1.84) −1.25 (1.59) 0.75B
Total score Visit 5 −12.18 (13.56) −11.54 (13.93) 0.74A
Visit 6 −16.02 (16.04) −15.31 (15) 0.74A
Visit 7 −17.57 (17.21) −17.77 (13.47) 0.92A
Patient’s global assessment
Visit 5 −15.11 (18.22) −17.51 (23.72) 0.91B
Visit 6 −23.15 (21.88) −24.64 (22.55) 0.86B
Visit 7 −26.91 (24.34) −30.1 (21.75) 0.32A
Investigator’s global assessment
Visit 5 −21.86 (20.07) −21.1 (22.08) 0.71B
Visit 6 −27.66 (19.75) −28.24 (23.44) 0.93B
Visit 7 −33.23 (20.92) −32.52 (22.89) 0.82A
100 mm VAS on pain
Rest pain Visit 5 −12.88 (22.64) −15.18 (24.51) 0.51B
Visit 6 −20.81 (22.75) −23.1 (24.43) 0.49A
Visit 7 −21.69 (24.53) −27.49 (23.69) 0.09A
Night pain Visit 5 −15.07 (23.5) −13.96 (23.28) 0.87B
Visit 6 −21.83 (26.37) −23.93 (22.41) 0.54A
Visit 7 −23.28 (27.72) −25.27 (21.16) 0.56A
Motion pain Visit 5 −15.83 (20) −17.06 (24.32) 0.59B
Visit 6 −22.67 (23.95) −25.86 (23.46) 0.34A
Visit 7 −25.93 (26.59) −29.62 (22.21) 0.28A
Range of Knee Motion (°)
Visit 5 135.39 (9.07) 134.02 (9.65) 0.27B
Visit 6 135.29 (8.88) 134.35 (9.25) 0.46B
Visit 7 135.71 (8.62) 134.99 (9.23) 0.51B
Swelling
Visit 5 18 (16.22) 22 (22.68) 0.24C
Visit 6 14 (12.61) 17 (17.53) 0.32C
Visit 7 16 (14.41) 12 (12.37) 0.67C
Tenderness
Visit 5 33 (29.73) 38 (39.18) 0.15C
Visit 6 31 (27.93) 28 (28.87) 0.88C
Table 2 Mean changes in secondary endpoints from baseline to
follow-up visits (Per-protocol Set) (Continued)
Visit 7 24 (21.62) 24 (24.74) 0.59C
Data are mean (SD) except for swelling and tenderness, both of which are
presented as number of patients (%)
A, P-value obtained from two-sample t-test; B, P-value obtained from Wilcoxon’s
rank sum test; C, P-value obtained from Chi-square test
Table 3 Responder rate (Per-protocol Set)
HMWHA XLHA P-valueA
N = 111 (%) N = 97 (%)
Decrease in weight-bearing pain
≥ 20 mm or ≥ 40% improvement
Visit 5 52 (46.85) 46 (47.42) 0.93
Visit 6 66 (59.46) 70 (72.16) 0.05
Visit 7 76 (68.47) 73 (75.26) 0.28
OMERACT-OARSI response
Visit 5 38 (34.23) 28 (28.87) 0.41
Visit 6 48 (43.24) 47 (48.45) 0.45
Visit 7 55 (49.55) 57 (58.76) 0.18
A, P-value obtained from Chi-square test
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activities, knee function, WOMAC total score and sub-
scale scores, patient’s and investigator’s global assess-
ments, and severity of swelling and tenderness in the
knee joint. No significant between-group difference in
the secondary efficacy endpoints was observed. Although
statistical significance was not identified, it was note-
worthy that OMERACT-OARSI responder rate (59% vs.
50%, P = 0.184) and WBP responder rate (75% vs. 68%,
P = 0.279) were slightly higher with XLHA than with
HMWHA.
The results of this study showed significant clinical
improvement with both treatments at 6 weeks after the
last injection. The improvement at 6 weeks was greater
than that observed at 1 week after the last injection, and
maintained until 12 weeks after the last injection. This
Table 4 Number of patients experiencing adverse events at
system organ class





Eye disorders 1 (0.7) 3 (2.2)
Gastrointestinal disorders 9 (6.2) 4 (2.9)
General disorders and administration site
conditions
4 (2.7) 9 (6.5)
Infections and infestations 9 (6.2) 13 (9.4)
Injury, poisoning and procedural
complications
2 (1.4) 3 (2.2)
Investigations 0 (0) 2 (1.4)
Metabolism and nutrition disorders 1 (0.7) 1 (0.7)
Musculoskeletal and connective tissue
disorders
15 (10.3) 12 (8.6)
Neoplasms benign, malignant and unspecified
(including cysts and polyps)
0 (0) 1 (0.7)
Nervous system disorders 6 (4.1) 5 (3.6)
Psychiatric disorders 1 (0.7) 0 (0)
Respiratory, thoracic and mediastinal disorders 4 (2.7) 2 (1.4)
Skin and subcutaneous tissue disorders 1 (0.7) 6 (4.3)
Surgical and medical procedures 1 (0.7) 1 (0.7)
Vascular disorders 1 (0.7) 1 (0.7)
Table 5 Number of patients experiencing common adverse
Events (>1% of Population)
Preferred Term HMWHA XLHA
N = 146 (%) N = 139 (%)
Diarrhoea 3 (2.1) 1 (0.7)
Dyspepsia 1 (0.7) 2 (1.4)
Injection site pruritus 2 (1.4) 1 (0.7)
Pain 1 (0.7) 4 (2.9)
Pyrexia 0 (0) 3 (2.2)
Cystitis 2 (1.4) 2 (1.4)
Nasopharyngitis 3 (2.1) 7 (5)
Upper respiratory tract infection 0 (0) 3 (2.2)
Joint swelling 0 (0) 2 (1.4)
Musculoskeletal pain 0 (0) 2 (1.4)
Pain in extremity 6 (4.1) 3 (2.2)
Plantar fasciitis 0 (0) 2 (1.4)
Headache 5 (3.4) 1 (0.7)
Paraesthesia 0 (0) 2 (1.4)
Cough 3 (2.1) 0 (0)
Erythema 0 (0) 2 (1.4)
Table 6 Adverse drug reactions
Adverse Drug Reactions HMWHA XLHA P-value
N = 146 N = 139
Injection site pruritus 1 (1) 1 (1)A 1.00
Pain 0 (0) 1 (2)A 0.49
Swelling 0 (0) 1 (1) 0.49
Injection site hemorrhage 0 (0) 1 (1) 0.49
Joint swelling 0 (0) 1 (1) 0.49
Erythema 0 (0) 2 (2)A 0.24
Total number 1 (1) 7 (8) 0.03
Data are number of patients experiencing adverse drug reaction and the
numbers in parenthesis are number of events
A, In XLHA group, 3 adverse drug reactions (each event of injection site
pruritus, pain, and erythema) occurred after placebo injection, which preceded
XLHA injection
Table 7 Number of patients experiencing solicited local reactions
at the injection site
HMWHA XLHA P-value
N = 146 (%) N = 139 (%)
After 1st Injection 58 (39.7) 52 (37.4) 0.69
Redness 27 (18.5) 21 (15.1) 0.45
Swelling 13 (8.9) 10 (7.2) 0.60
Pain 38 (26) 44 (31.7) 0.29
Warmth 23 (15.8) 23 (16.5) 0.86
After 2nd Injection 43 (29.9) 40 (29.4) 0.93
Redness 18 (12.5) 16 (11.8) 0.85
Swelling 6 (4.2) 5 (3.7) 0.83
Pain 30 (20.8) 27 (19.9) 0.84
Warmth 16 (11.1) 13 (9.6) 0.67
After 3rd Injection 38 (27.1) 40 (29.4) 0.68
Redness 17 (12.1) 14 (10.3) 0.63
Swelling 11 (7.9) 11 (8.1) 0.94
Pain 31 (22.1) 34 (25) 0.58
Warmth 12 (8.6) 17 (12.5) 0.29
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course of changes in the clinical efficacy is in agreement
with a meta-analysis of 54 clinical trials that included
data from 7545 patients [4], which showed IAHA was
efficacious by 4 weeks, reached its maximum efficacy by
8 weeks, and its efficacy was maintained up to 24 weeks.
Likewise, the degree of change in WBP observed in the
present study (−33.3 mm with XLHA and −29.2 mm
with Hyruan Plus® at 12 weeks) was similar to the previ-
ous studies using HMWHA [19] or other high molecular
weight (1000–7000 KDa) HA preparations (Orthovisc®
[25] and Artzal® and Synvisc® [26]). In the study with
Orthovisc®, IAHA was compared with methyl prednisol-
one acetate (MPA) and the results in terms of all pain
scores and Lequesne index at 3 month favoured IAHA
but no between-group difference was found at 6 month.
A BDDE cross-linked HA preparation (Durolane®) simi-
lar to XLHA was investigaed in patients with knee OA
against MPA; its efficacy in terms of WOMAC pain re-
sponder rate at 12 weeks was non-inferior to that of
MPA; and the benefit of IAHA was maintained up to
26 weeks while that of MPA was reduced [27]. It is note-
worthy that a single injection of the cross-linked HA
(60 mg) was enough to maintain its effect until 26 weeks
whereas repeated injections of the linear HA (30 mg/in-
jection) were needed to obtain similar efficacy brought
by the same number of injections of MPA [27]. Unlike
the un-modified HA, which undergoes rapid degradation
enzymatically [28] or by oxidation [29], the cross-linked
HA has slow degradation rate and increased elastovis-
cous properties, thus extended durability at the injection
site [1]. As injection procedure itself bears risks of infec-
tion, pain and/or bleeding, reducing the injection num-
bers while obtaining comparable efficacy is a reasonable
ground for choice of a cross-linked HA unless safety is-
sues come up with cross-linking agents. The LBSA0103
is produced using BDDE as the cross-linking agent,
which has reactive epoxide groups in either side of chain
but these are neutralized after forming stable ether
bonds with alcohol in the HA backbone [30] and the
amount of unreacted BDDE is negligible. Therefore,
safety risk associated with chemical states of BDDE
present after cross-linking reaction is very low and the
safety and metabolism of BDDE cross-linked HA have
been well established.
No remarkable safety issue was identified in this study
and the safety profile obtained was consistent with those
observed with other IAHA preparations [31]. The inci-
dence of solicited local injection site reactions and the
incidence of treatment-emergent adverse events were
similar in both groups. Both IAHA preparations used in
this study are non-animal origin, which may have con-
tributed to the favourable safety profile due to low risk
of developing immunological response. In a double-
blind, randomized study comparing fermented (bacterial
origin) HA with avian origin HA, injection site effusions
were less frequent with fermented HA than with avian-
origin HA (0.6% vs. 8.1%, P = 0.002) [32].
Despite the wealth of available data, efficacy of IAHA is
still in debate and available guidelines [6, 7, 33] do not
present consistent recommendation. Several studies using
placebo comparator showed contradictory results and this
made the data interpretation challenging [8, 9, 29, 34–38].
In a study by Jørgensen et al. [35], 337 patients with mod-
erate to severe knee OA received five injections of a low
MW HA (Hyalgan®) or saline and were followed up at 3,
6, 9 and 12 months after the treatment. But IAHA did not
show better improvement in pain, function, acetamino-
phen consumption, or other efficacy parameters than sa-
line injections. Another study where the same product
was compared with placebo and naproxen (500 mg orally
twice a day) in 495 patients with knee OA, however,
showed significantly greater improvement with IAHA in
pain on the 50-foot walk than placebo and more IAHA–
treated patients (48%) had slight pain or were pain free
than placebo-treated (33%) or naproxen-treated (37%) pa-
tients at 26 weeks after the treatment [34]. In studies using
high MW HA in comparison with placebo, some degree
of placebo effect was also observed; however, IAHA had
better results than placebo for certain efficacy endpoints
(WOMAC pain sub-score on walking [36] and efficacy
durability by Kaplan–Meier analysis [29]). Even in several
meta-analyses in which data from most of representative
placebo-controlled trials of IAHA were combined, a de-
finitive conclusion was not made and mixed results were
presented [8, 9, 37, 38] like following: IAHA did not prove
clinically significant efficacy and showed greater risk of ad-
verse events than placebo [8]; small efficacy observed with
IAHA might have been overestimated due to publication
bias and high molecular weight HA was more effacious
than low molecular weight HA but heterogeniety of the
studies limited the definite conclusion [9]; IAHA had
moderate efficacy compared with placebo until 10 weeks
but not at 15 to 22 weeks [37]; or significant improvement
in pain and functional outcomes were observed with
IAHA but the efficacy was overestimated in low methodo-
logical quality of studies [38]. This inconclusive results
may be mainly attributed to variety in the IAHA products,
variable disease severity, difference in study designs, injec-
tion regimens, outcomes evaluation criteria, and rescue
medication used in the studies included or not in the ana-
lyses. Further studies are needed to answer the question
on the efficacy of IAHA considering various factors men-
tioned above.
Some limitations of the present study need to be
addressed. First, two injections of placebo saline were
mixed in the study arm. As HMWHA requires three
weekly injections whereas XLHA only needs to be injected
once, placebo injections in the study arm were inevitable
Ha et al. BMC Musculoskeletal Disorders  (2017) 18:223 Page 8 of 10
to maintain double-blind status which was critical to
maintain objectiveness of this study. Second, the period of
3 months follow-up may seem to be short. There have
been some studies that evaluated the effect of hyaluronate
in patients with knee OA about 3 months and the effect
of HA is known to be shown between 5 and 12 weeks
[39–41]. In addition, the extension of follow-up period
could increase a drop-out rate, which might increase the
bias obtaining optimal data in this kind of clinical trial.
Based on these points, the evaluation period of this clin-
ical trial was determined by a consensus with the govern-
ment regulatory authority and IRBs of the participating
institutions. Finally, 12 centers may seem to be too many.
However, all investigators adhered to the protocol of this
clinical trial without major violations. As this study evalu-
ated a novel XLHA substance for a single injection ther-
apy, multi-centers were needed to enroll the more than
300 subjects in a reasonable study period.
Conclusions
The present study demonstrated that a single injection
of XLHA was non-inferior to three weekly injections of
HMWHA in terms of WBP reduction, and supports
XLHA as an effective and safe treatment for patients
with mild to moderate knee OA. Although this study
has provided an evidence regarding the efficacy of
IAHA, generalisation of the results of this study could
be made after obtaining more supporting data from fur-
ther researches that will focus on the durability of IAHA
beyond 12 weeks and comparative study on the efficacy
of variable IAHA preparations.
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